High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on ...

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer's marketing ...

Pfizer's ex-chair and chief executive Ian Read ... GBT acquisition after the main asset in that $5.4 billion deal – Oxbryta for sickle cell disease – was pulled from the market last month.

Pfizer Inc. discovers, develops ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under ...

About Pfizer Inc. and Eli Lilly and Company Pfizer Inc. discovers ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable ...

The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...